Aurion Biotech, Inc. (AURN)

Aurion Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	-	12.53	10
Research & Development	-	34.82	24.57
Operating Expenses	-	47.35	34.57
Operating Income	-60.37	-47.35	-34.57
Interest Expense / Income	-1.1	-1.9	-0.18
Other Expense / Income	0.6	-	1.29
Pretax Income	-59.88	-45.45	-35.68
Income Tax	0.04	0.1	0
Net Income	-59.92	-45.55	-35.69
Free Cash Flow	-52.67	-42.61	-33.86
EBITDA	-60.28	-46.79	-34.6
Depreciation & Amortization	0.7	0.56	1.27
EBIT	-60.98	-47.35	-35.87

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).